Overview
- A planned interim analysis reported at ASCO found the STRIDE regimen (tremelimumab plus durvalumab) given with lenvatinib alongside transarterial chemoembolization cut the risk of progression or death by about 30% versus TACE alone.
- The study reported improved median progression-free survival in the combination arms, with figures cited around 13.0 months versus 9.8 months and 12.9 months versus 8.1 months in the comparisons presented.
- Durability signals were encouraging, with the trial’s principal investigator saying nearly one-third of patients who received dual immunotherapy with or without lenvatinib remained alive and progression-free at two years.
- Overall survival showed a favorable but immature trend that was not formally tested at the interim readout, and the trial will continue to collect events and monitor secondary endpoints before drawing conclusions about survival.
- A pre-planned exploratory analysis suggested a larger PFS benefit in patients with non-viral liver disease, AstraZeneca signaled interest in studying STRIDE earlier in care, and the data release coincided with a modest drop in the company’s shares.